Mikkel Pedersen Joins Commit Biologics as Chief Scientific Officer

Commit Biologics has announced the appointment of Dr. Mikkel Wandahl Pedersen as its new Chief Scientific Officer (CSO) to lead the company’s efforts in antibody-based drug discovery and development. With over two decades of experience in immuno-oncology and autoimmune diseases, Dr. Pedersen brings a wealth of expertise to Commit as it advances its Bispecific Complement Engaging (BiCE™) technology, designed to activate the complement system for targeted destruction of tumor cells or those implicated in autoimmune disorders.

Dr. Pedersen most recently served as CSO at Nykode Therapeutics, where he led the company’s research strategy, expanded its R&D team, and established key partnerships. Before Nykode, he was the CSO at Symphogen, where he played a pivotal role in antibody discovery and advancing several products through to clinical trials. His experience includes developing numerous oncology antibody programs and vaccines, including COVID-19 and HPV cancer vaccines.

Krishna Polu, CEO of Commit Biologics, expressed confidence in Dr. Pedersen’s leadership, citing his proven track record in drug discovery and R&D team building. Dr. Pedersen will focus on advancing Commit’s BiCE platform as the company moves towards nominating its first drug candidate. Founder and Board Member Nick Laursen, who previously served as CSO, will transition to the role of Head of Discovery, emphasizing that Dr. Pedersen’s expertise will drive Commit forward in developing innovative therapies.